Cancer diagnostics player Kiyatec is joining forces with Mayo Clinic to combine their complementary technologies for ovarian cancer care. Mayo Clinic is enrolling for a trial to assess whether living tumor samples generated from patient-derived xenografts can determine which chemotherapy is most effective for individual patients. Meanwhile, Kiyatec uses its 3-D cell culture platform to generate patient-specific data to predict their response to particular drugs. The hope is the collaboration will allow more patients to receive personalized ovarian cancer treatment thanks to these response models. Release
> Surmodics will add 100 new jobs in Galway, Ireland over the next 5 years. Story
> Sleep disorder device maker Oventus prices its IPO on the Australian Securities Exchange at $12 million. Release
> The U.K.'s NHS will acquire 7 TomoTherapy Systems from Accuray ($ARAY). Release